Breaking News

State-owned BIBCOL set to begin production of Bharat Bio’s Covaxin by February 2022

Bharat Immunological and Biological Corporation (BIBCOL) – one of three public sector companies associated with the production of Covaxin Bharat Biotech amid a shortage of Covid-19 vaccine – will begin production next year, a senior official said.

“February 2022 is the target date for the trial batch, after which we will apply for regulatory approvals,” said BIBCOL Chairman J.K. Gupta. “After that, we will begin full production of covaxin, which will be 10 million doses per month.” Two other companies that will help increase Covaxin’s production capacity: Haffkine Bio-Pharmaceutical Corporation, Mumbai, and Indian Immunologicals (IIL), Hyderabad.

The government is currently betting that the Indian Immunologicals will increase production of covaxin this year as Haffkine Bio-Pharma manager Sandeep Rathod previously assumed it would take a year to develop a vaccine.

“We expect Indian Immunologicals to start producing covaxin by the end of this year,” a senior government official told ET.

BIBCOL

Bharat Biotech signed a technology transfer agreement to enable these firms to manufacture Covaxin injections. Gupta said BIBCOL has appointed a consultant to modernize its plant in Bulandshahr, Uttar Pradesh, and construction work is ongoing. “The update will start shortly and by February next year we expect to have the first trial batch of the vaccine out,” he said.

Leave a Reply